Search
for
Sort by
Research 241–270 of 648
- The Percentage of Free PSA and Urinary Markers Distinguish Prostate Cancer from Benign Hyperplasia and Contribute to a More Accurate Indication for Prostate Biopsy
- Efeitos do uso da finasterida sobre o volume prostático e dosagem sérica do PSA em pacientes jovens
- Effects of the use of finasteride on prostate volume and serum PSA in young patients
- UP-02.010 Urinary PSA: Marker of Benign Prostatic Hyperplasia?
- Modelling of the composition of emulsion medicines and cosmetics stabilized by a biocomplex of surfactant substances based on rhamnolipids Pseudomonas sp. PS-17
- FINASTERIDE AND PSA
- Επικύρωση της χρησιμότητας των νεότερων παραμέτρων του PSA ορού για την ανίχνευση του καρκίνου του προστάτη
- 1450 THE TRUE BENEFIT OF PSA-SCREENING: MODELING THE IMPACT OF TRIAL SETTING AND PROTOCOL ON MORTALITY
- 42134 Long-term Efficacy of Guselkumab (GUS) on Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study in Biologic-naïve Patients With Psoriatic Arthritis (PsA)
- The Effect of 5α-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men
- The Effects of Transdermal Dihydrotestosterone in the Aging Male: A Prospective, Randomized, Double Blind Study
- Urinary Retention in Patients with BPH Treated with Finasteride or Placebo over 4 Years
- Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial
- Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate
- Acute urinary retention: risks and management.
- 5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review
- Finasteride-its impact on sexual function and prostate cancer
- Dutasteride for the treatment of benign prostatic hyperplasia
- Ganoderma lucidum is an inhibitor of testosterone-induced prostatic hyperplasia in rats
- Finasteride: The First 5α-Reductase Inhibitor
- Primary Scarring Alopecia: Clinical-Pathological Review of 72 Cases and Review of the Literature
- Relationship of Early-Onset Baldness to Prostate Cancer in African-American Men
- Corn silk extract improves benign prostatic hyperplasia in experimental rat model
- Medikamentöse Therapie des benignen Prostatasyndroms
- Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
- Benign prostatic hyperplasia and male lower urinary symptoms: A guide for family physicians
- Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26 years old
- The Relationship Between Metformin and Serum Prostate‐Specific Antigen Levels
- Finasterida: Diez Años De Uso Clínico. Revisión Sistemática De La Literatura
- Dutasteride, a novel dual 5-A reductase inhibitor, reduces serum DHT to a greater extent versus finasteride and achieves finasteride maximal reduction in a larger proportion of patients